Corify Care has announced a “major clinical milestone” with the publication of two studies in the journals Heart Rhythm and EP Europace validating its proprietary technology as a “highly accurate solution” for mapping both atrial and ventricular arrhythmias in a single beat, as per a press release from the company.
While current arrhythmia mapping is often slow, requiring the induction of unstable rhythms or reliance on preprocedural imaging, Corify says its Acorys mapping system “eliminates this trade-off” by capturing global cardiac electrical activity instantly and providing actionable insight before ablation begins.
Acorys is described by the company as an imageless, non-invasive cardiac mapping platform capable of delivering a global, four-chamber view of cardiac electrical activity in real time.
“Time and predictability are the most valuable assets in the EP [electrophysiology] lab,” said Corify chief executive officer (CEO) Andreu Climent. “These publications prove that we can give physicians the full picture upfront, without delay. This is a fundamental shift from mapping to knowing.”
The NIAVAS study—published in Heart Rhythm—demonstrates that Corify’s technology successfully identifies the arrhythmogenic substrate of ventricular tachycardia (VT) while the patient is in normal sinus rhythm, eliminating the need to induce haemodynamically unstable arrhythmias. Additionally, the EP Europace study validates the system’s ‘imageless’ approach for specific atrial arrhythmias, delivering highly accurate, full-chamber activation maps without pre-acquired computed tomography (CT) or magnetic resonance imaging (MRI) scans.
“We are eliminating guesswork in complex ablation,” said Jana Reventós, Corify’s clinical affairs manager and a leading author for both studies. “For the first time, clinicians can see arrhythmia circuits instantly—without imaging dependencies or procedural risk—enabling confident, targeted intervention from the outset.”
“With Corify’s technology, we see the full arrhythmia substrate instantly and continuously, which translates into more targeted ablation, shorter procedures, and less risk for the patient,” added Ivo Roca-Luque (Hospital Clínic de Barcelona, Barcelona, Spain).
In addition to having previously gained a CE mark in Europe, the Acorys mapping system received 510(k) clearance from the US Food and Drug Administration (FDA) earlier this month. Corify is now initiating a phased US commercial rollout of the system.
“Acorys gives us something we’ve never had before—a complete understanding of the arrhythmia before we even start ablating,” said Felipe Atienza, chief medical officer and co-founder of Corify, speaking after the US FDA clearance. “This has the potential to dramatically change how we approach complex cases, particularly in VT and atrial tachyarrhythmias.”
